Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®
Public ClinicalTrials.gov record NCT02499900. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
CONFIDENCE: A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With Subcutaneous Injections of Copaxone(R) (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to compare patient medication satisfaction as measured by the Medication Satisfaction Questionnaire (MSQ) scores between the Copaxone 40 mg/mL three time a week (TIW) group and the Copaxone 20 mg/mL once daily (QD) group over 6 months of treatment.
Study identification
- NCT ID
- NCT02499900
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 861 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 10, 2015 (Actual)
- Primary completion
- Jan 10, 2017 (Actual)
- Completion
- Jun 2, 2017 (Actual)
- Last update posted
- Dec 9, 2021
2015 – 2017
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 13485 | Cullman | Alabama | 35058-1565 | — |
| Teva Investigational Site 13524 | Carmichael | California | 95608 | — |
| Teva Investigational Site 13478 | Atlanta | Georgia | 30327 | — |
| Teva Investigational Site 13475 | Northbrook | Illinois | 60062 | — |
| Teva Investigational Site 13472 | Foxborough | Massachusetts | 02035 | — |
| Teva Investigational Site 13479 | Golden Valley | Minnesota | 55422 | — |
| Teva Investigational Site 13483 | Golden Valley | Minnesota | 55422 | — |
| Teva Investigational Site 13487 | Las Vegas | Nevada | 89106 | — |
| Teva Investigational Site 13470 | Teaneck | New Jersey | 07666 | — |
| Teva Investigational Site 13482 | New Hyde Park | New York | 11042 | — |
| Teva Investigational Site 13471 | Raleigh | North Carolina | 27607 | — |
| Teva Investigational Site 13473 | Columbus | Ohio | 43214 | — |
| Teva Investigational Site 13477 | Uniontown | Ohio | 44685 | — |
| Teva Investigational Site 13481 | Round Rock | Texas | 78681 | — |
| Teva Investigational Site 13480 | Virginia Beach | Virginia | 23456 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 82 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02499900, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 9, 2021 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02499900 live on ClinicalTrials.gov.